Condition: Breast Cancer · Sponsor: Hebei Medical University Fourth Hospital
This study is a multi-center, observational, real-world study. We planned to recruit 420 HR+ locally advanced or metastatic breast cancer patients who had received or had not received prior systemic therapy. All patients included in the analysis were receiving or planning to receive dalpiciclib-containing regimens without restrictions, completely following the physician 's clinical choice, to assess the efficacy and safety of dalpiciclib-containing regimens.
This description comes directly from the study's public registry record.
cuizhi Geng Cuizhi Geng, archiater · +8613503216325 · gengcuizhi@hotmail.com
Always discuss trial participation with your own doctor first.
| The Fourth hospital of Hebei University | Shijiazhuang, Hebei, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05578053